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 Abstract 
Background: Patients with Barrett’s esophagus may be at increased risk of mortality overall, and 
cardiovascular disease has been suggested as the main underlying cause of death.  
Aim: To examine cause-specific mortality and risk of cardiovascular events among patients with Barrett’s 
esophagus. 
Methods: Utilizing existing Danish data sources (1997-2011), we identified all patients with histologically 
verified Barrett’s esophagus (n=13,435) and 123,526 members of the general population matched by age, 
sex, and individual comorbidities. We calculated cause-specific mortality rates and incidence rates of 
cardiovascular diseases. We then compared rates between patients with Barrett’s esophagus and the 
general population comparison cohort, using stratified Cox proportional hazard regression. 
Results: Patients with Barrett’s esophagus had a 71% increased risk of overall mortality. The cause-specific 
mortality rate per 1,000 person-years for patients with Barrett’s esophagus was 8.5 for cardiovascular 
diseases, 14.7 for non-esophageal cancers, and 5.4 for esophageal cancer. Compared to the general 
population cohort, corresponding hazard ratios were 1.26 (95% confidence interval (CI): 1.15-1.38), 1.77 
(95% CI: 1.65-1.90), and 19.4 (95% CI: 16.1-23.4), respectively. The incidence rates of cardiovascular 
diseases per 1,000 person-years for Barrett’s esophagus patients and for persons from the general 
population cohort, respectively, varied from 0.4 and 0.2 for subarachnoid bleeding (hazard ratio 1.10, 95% 
CI: 0.87-1.39) to 8.1 and 5.9 for congestive heart failure (hazard ratio 1.33, 95% CI: 1.21-1.46).  
Conclusion: Prophylactic measures targeted at cardiovascular diseases and non-esophageal cancers 
potentially could be more important than measures against esophageal cancer for improving prognosis 
among patients with Barrett’s esophagus. 
 Introduction 
Barrett’s esophagus is a premalignant condition of the distal esophagus characterized by replacement of 
normal squamous epithelium with columnar epithelium.1 Several recent studies have indicated that 
patients with Barrett’s esophagus have higher mortality than the general population, but that death due to 
esophageal malignancy is not the primary underlying cause.2-5 This is consistent with the finding that the 
annual malignant transformation rate in Barrett’s esophagus is approximately 0.2%.6-8 Evidence from 
different settings has indicated that cardiovascular diseases are the predominant underlying cause of death 
among patients with Barrett’s esophagus, probably partially exacerbated by shared risk factors such as 
obesity, smoking, and alcohol consumption.2, 3, 9-11  Given these findings, prophylactic screening for and 
treatment of cardiovascular diseases might be effective in patients with Barrett’s esophagus, and 
healthcare expenditures better utilized on prevention of cardiovascular diseases than on regular follow-up 
endoscopies to detect the rare event of esophageal cancer. However, only sparse and conflicting 
population-based evidence exists on mortality in patients with Barrett’s esophagus.2, 12-14 Furthermore, 
studies of causes of death, including cardiovascular death, are generally susceptible to misclassification. 
Thus there is a need for assesment of the association between Barrett’s esophagus and cardiovascular 
events.15, 16  In this context, we utilized a nationwide population-based cohort of histologically verified 
Barrett’s esophagus patients6 first to examine overall and cause-specific mortality among patients with this 
condition and second to estimate their risk of cardiovascular events.   
 Materials and Methods 
We conducted this matched cohort study in the setting of the entire Danish population. During the study 
period (January 1, 1997 - December 31, 2011), the cumulative population numbered 6,849,900 people. 
Individual-level data were linked using the unique 10-digit personal identifier assigned at birth or upon 
immigration to all Danish residents by the Danish Civil Registration System.17 
 
Barrett’s esophagus cohort 
We used the Danish Pathology Registry to identify a cohort consisting of all Danish patients with 
histologically verified Barrett’s esophagus during the 1997-2011 period.6, 18 Since January 1, 1997, this 
Registry has recorded data on all pathology examinations conducted in Denmark, including date of 
examination, unique ID number of the specimen, the pathology department code, and diagnosis based on 
the Danish Systemized Nomenclature of Medicine (SNOMED) codes. Patients joined the cohort on the date 
of their first diagnosis of Barrett’s esophagus (index date). (See Supplementary Table s1 for diagnosis 
codes.) We excluded patients with a previous diagnosis of myocardial infarction, stroke, venous 
thromboembolism, or heart failure, as these diseases comprised secondary study endpoints. Patients with 
Barrett’s esophagus were categorized in a time-varying manner according to severity of histology, i.e., low-
grade dysplasia, high-grade dysplasia, and esophageal cancer. We lacked information on the endoscopic 
appearance of the esophagus or the length of Barrett’s lesions.    
 
Population comparison cohort 
We used the Danish Civil Registration System19 to match each patient with Barrett’s esophagus with 10 
persons from the general population who were alive and without a Barrett’s esophagus diagnosis on the 
corresponding patient’s diagnosis date (index date). Matching criteria were age (5-year intervals), sex, and 
the individual conditions included in the Charlson Comorbidity Index (CCI) . We applied the same exclusion 
criteria to the comparison cohort as for the Barrett’s cohort.  In the event that an individual from the 
 comparison cohort developed Barrett’s esophagus during the study period, follow-up time was terminated 
and the individual joined the Barrett’s cohort.  
 
Study endpoints 
Our primary endpoint was mortality, with information on date of death obtained from the Civil Registration 
System.19 We ascertained causes of death from the Danish Causes of Death Registry, which has recorded all 
deaths in Denmark since 1970.15 This Registry codes causes of death according to International 
Classification of Diseases, Tenth Revision (ICD-10) codes. We categorized patients according to their 
underlying cause of death, i.e., neoplasms overall, non-esophageal cancer, esophageal cancer, circulatory 
system conditions, respiratory system conditions, digestive system conditions, all other causes, and 
unknown causes. (See Supplementary Table s1 for codes.) We also subcategorized causes of cancer deaths 
by specific cancer site.  
Secondary endpoints were cardiovascular events, defined as a first-time diagnosis code of myocardial 
infarction, stroke, venous thromboembolism, or heart failure. (See Supplementary Table s1 for codes.) We 
obtained relevant data from the Danish National Patient Registry20 which has tracked all non-psychiatric 
hospitalizations in Denmark since 1977 and outpatient hospital contacts since 1995. The Danish National 
Patient Registry records dates of admission and discharge and up to 20 discharge diagnoses, coded by 
physicians according to ICD codes (ICD-8 until the end of 1993 and ICD-10 thereafter).   
 
Comorbidity 
We defined comorbidities according to the diagnoses included in the CCI, as recorded in the Danish 
National Patient Registry.21 The CCI assigns weights between one and six to a range of conditions. (See 
Supplementary Table s2). The conditions included in the CCI were not only considered individually for 
matching and analysis, but also as the components of a summed aggregate score that we classified as 
follows: score of 0 (no comorbidity), score of 1 (low comorbidity), and score 2 or more (high comorbidity). 
 In addition to the conditions in the CCI, we included information on prior diagnoses of atrial 
fibrillation/flutter, obesity, hypertension, and alcoholism. (See Supplementary Table s1 for codes.) 
 
Statistical analyses 
Barrett’s patients and members of the population comparison cohort were followed from index date until 
endpoint date, emigration, or end of the study, whichever came first. We calculated mortality rates and 
incidence rates of cardiovascular diseases as the number of events divided by follow-up time.  We used 
stratified Cox proportional hazard models to compute hazard ratios of mortality and cardiovascular events, 
comparing patients in the Barrett’s cohort to individuals in the general population cohort. We computed 
hazard ratios for the first year of follow-up and for the second and subsequent years of follow-up 
separately to examine short-term vs. long-term mortality/risks. We also conducted an analysis excluding 
patients diagnosed with esophageal cancer up to 30 days after the index date.  
We controlled for differences in age, sex, and comorbidity through matching and additionally adjusted for 
atrial fibrillation, hypertension, obesity, and alcoholism.  In further analyses we did not adjust for atrial 
fibrillation and hypertension, since these factors may be intermediate factors along the causal pathway for 
the association of interest. In a time-varying analysis, we estimated mortality and risk of cardiovascular 
diseases by the histological severity of Barrett’s esophagus according to the following categories: no 
dysplasia, low-grade dysplasia, high-grade dysplasia, and cancer. Patients contributed risk-time according 
to the histological severity of their Barrett’s lesions at the beginning of follow-up and changed to a new 
category only in the event of increasing histological severity. To conduct this analysis, we dissolved the 
matching and adjusted for the matching factors. 
In a subsequent analysis conducted to reduce bias due to uncontrolled confounding by lifestyle factors, we 
examined the relation between Barrett’s esophagus and mortality and cardiovascular events among 
subgroups of patients with diagnoses of chronic obstructive pulmonary disease (surrogate for smoking) or 
alcoholism.    
 Results 
We identified 13,427 patients with Barrett’s esophagus and 123,526 persons from the general population, 
matched by age, gender, year of index date, and individual conditions in the CCI. Because we were unable 
to match all patients with Barrett’s esophagus to 10 persons from the general population, small differences 
occurred between the characteristics of the Barrett’s esophagus cohort and the general population 
comparison cohort (Table 1).  Among patients with Barrett’s esophagus and members of the general 
population cohort, median age on the diagnosis/index date was 61 and 60 years, respectively, and average 
follow-up was 4 and 5 years, respectively. The vast majority (>80%) of patients with Barrett’s esophagus did 
not have dysplasia at diagnosis or during the course of follow-up.  
Mortality 
Patients with Barrett’s esophagus generally had higher rate of mortality than subjects in the matched 
general population cohort (Figure 1 and Table 2). The overall mortality rate was 46.7 per 1,000 person-
years among patients with Barrett’s esophagus and 27.2 per 1,000 person-years among subjects from the 
general population cohort, corresponding to an adjusted hazard ratio of 1.71 (95% CI: 1.64-1.78). The 
hazard ratio was nearly 3.2-fold increased in the first year of follow-up, but only 1.4-fold increased in the 
second and subsequent years of follow-up. For patients with Barrett’s esophagus, the highest mortality 
rates were associated with non-esophageal cancer and diseases of the circulatory system. These two causes 
of deaths also were associated with the highest mortality rates in the general population cohort, although 
to a lesser degree (Table 2). The mortality rate for esophageal cancer was the third highest among all 
causes of death for patients with Barrett’s esophagus (disregarding the category of ‘all other causes’), while 
among subjects in the general population cohort, esophageal cancer had the lowest rate of all major causes 
of deaths. In a subanalysis, Barrett’s esophagus patients with known esophageal cancer were excluded as 
of the Barrett’s esophagus diagnosis date (Supplementary Table S3). In this subanalysis, the mortality rate 
 for esophageal cancer decreased from 5.4 to 2.1 per 1,000 person-years among Barrett’s patients, and 
esophageal cancer was associated with the lowest mortality rate of the major causes of death in this group.    
Generally, the hazard ratios comparing cause-specific mortality among patients with Barrett’s esophagus 
and members of the general population cohort were increased. This was most pronounced for esophageal 
cancer even when we excluded patients with known esophageal cancer at diagnosis and diseases of the 
digestive system (Table 2 and Supplementary Table S3). When we calculated hazard ratios without 
adjusting for atrial fibrillation and hypertension, the results did not change (not shown). Among non-
esophageal cancers, malignancies of the stomach, colorectum, lungs and thorax, and lymphoid, 
hematopoietic and other sites had the highest rates (Table 3).  
When Barrett’s esophagus was evaluated by histological severity, the overall mortality rate increased with 
increasing histological severity. This pattern also was observed for mortality caused by neoplasia, 
particularly esophageal cancer (Table 4). For esophageal cancer, the mortality rate was very low in the 
absence of dysplasia and for patients with low-grade dysplasia. It was only among Barrett’s patients with 
esophageal cancer that the mortality rate associated with this cancer exceeded the mortality rate 
associated with diseases of the circulatory system. We had too few observations to support an analysis of 
specific malignant causes of death according to severity of Barrett’s esophagus. When we evaluated deaths 
caused by diseases of the circulatory, respiratory, and digestive system, the mortality rates did not change 
substantially by severity of Barrett’s esophagus and the mortality rate ratios were only modestly increased.  
 
Cardiovascular diseases 
Table 5 displays the incidence rates and hazard ratios showing the association between Barrett’s esophagus 
and different secondary endpoints. In general, patients with Barrett’s esophagus were at modestly 
increased risk of cardiovascular diseases compared to individuals in the general population cohort. Hazard 
 ratios for secondary endpoints were very similar when the first year was compared to the second and 
subsequent years of follow-up, with the exception of risk of venous thromboembolism. Compared with the 
risks in the general population cohort, the risk of venous thromboembolism was 3.1-fold increased in the 
first year of follow-up and 1.4-fold increased in the second and subsequent years among Barrett’s 
esophagus patients. We found no substantial changes in risk of cardiovascular disease by histological 
severity of Barrett’s esophagus, although the risks appeared to increase slightly with increasing severity 
(Supplementary Table S4).  
 
Smoking and alcoholism 
Supplementary Tables S5 shows hazard ratios of mortality and cardiovascular events within subgroups of 
Barrett’s esophagus patients with chronic obstructive pulmonary disease (surrogate for smoking) and 
alcoholism, compared to the general population cohort. The hazard ratios were attenuated towards the 
null for mortality and a few cardiovascular events. This might indicate some residual confounding by 
smoking and alcohol intake in the overall analysis.  
 Discussion 
In this nationwide population-based cohort study of patients with histologically verified Barrett’s 
esophagus, we found that overall mortality was 3.2-fold increased in the first year after diagnosis and 1.4-
fold increased in the second and subsequent years, compared with an age-, sex-, and comorbidity- matched 
general population cohort. Cause-specific mortality rates in the Barrett’s esophagus cohort were highest for 
non-esophageal cancers and for cardiovascular diseases, followed by esophageal cancer. When patients 
with known esophageal cancer on the date of their Barrett’s esophagus diagnosis were excluded from the 
analysis, the mortality attributable to esophageal cancer was the lowest of the major causes of death 
among both the Barrett’s esophagus and general population cohorts. For non-esophageal cancers, several 
malignancies contributed to the high cancer mortality rate among Barrett’s esophagus patients. The 
histological severity of Barrett’s esophagus impacted mortality caused by neoplasia overall, but affected 
mortality from other causes only slightly.  We observed a modestly increased risk of cardiovascular events 
among Barrett’s esophagus patients, which was not substantially impacted by the histological severity of 
Barrett’s esophagus. The incidence rate of esophageal adenocarcinoma within our cohort of patients with 
Barrett’s esophagus has previously been shown to be 1.2 (95% CI: 0.9-1.5) per 1000 person-years.6 
Our findings of increased overall mortality compared to the general population are supported by a recent 
population-based study utilizing data from UK’s Clinical Practice Research Datalink.2 That study excluded 
deaths in the first year of follow-up and relied on Barrett’s diagnoses from general practitioners rather than 
histologically verified diagnoses. Using individuals without Barrett’s esophagus as the comparison group, 
the study reported a mortality ratio of 1.21 (95% CI: 1.14-1.30), after adjusting for sex, age at diagnosis, 
smoking, alcohol consumption, and body mass index. The study was an extension of a previous report by 
the same group and used the same data sources.12  Its findings accord with at least five non-population-
based studies.5,9, 10, 22, 23 In contrast to the present study, the UK study2 did not report an increased risk of 
cardiovascular death among patients with Barrett’s esophagus. However, it did find that diseases of the 
 circulatory system, followed by non-esophageal neoplasms, were the major underlying causes of death 
among patients with Barrett’s esophagus.  
Our study did not include data on treatment of Barrett’s esophagus. However, endoscopic ablative therapy 
was uncommon in our cohort during the study period.  Our findings on causes of death are consistent with 
those of a recently published study including 4,982 patients treated with radiofrequency ablation of 
Barrrett’s esophagus in the US.11 In that study, the most common causes of death were non-esophageal 
cancers and cardiovascular diseases.  
For unclear reasons, two previous population-based studies13, 14 found no increase in overall mortality for 
patients with Barrett’s esophagus compared to the general population. An analysis13 based on the 
Netherlands Cohort Study found an observed-to-expected ratio of overall mortality of 1.1 (95% CI: 0.9-1.2) 
after accounting for differences in age and sex, and a study14 conducted in Northern Ireland reported an 
age-standardized mortality ratio of 0.96 (95% CI: 0.84-1.07).  
The current study extends existing evidence on mortality through its precise estimates and long-term 
follow-up of a large, nationwide cohort of patients with histologically verified Barrett’s esophagus.  Our 
study also accounted for coexisting diseases and provided estimates according to histological severity. In 
addition, the study is the first to examine the specific association between Barrett’s esophagus and 
cardiovascular diseases. Such evidence is needed to foster an understanding of the possible increased risk 
of cardiovascular death among patients with Barrett’s esophagus and also to evaluate whether patients 
with Barrett’s esophagus should be offered cardiovascular screening or prophylactic treatment. Most, but 
not all, studies seem to agree that cardiovascular diseases are among the most frequent causes of death 
among patients with Barrett’s esophagus.2, 3, 9, 10 We also found high mortality related to non-esophageal 
cancers. Our findings, together with those of earlier studies, suggests that prophylactic measures against 
cardiovascular diseases and appropriate screening for non-esophageal cancers potentially could be even 
more important for improving the prognosis of patients with Barrett’s esophagus, than prophylactic 
 measures against esophageal cancer, including surveillance endoscopy. This is especially true when one 
considers the questionable effectiveness of surveillance endoscopy in preventing death from esophageal 
adenocarcinoma.24  
A previous population-based study reported a decreased risk of stroke death among patients with Barrett’s 
esophagus. It speculated that individuals with low vascular tone, and hence low blood pressure and stroke 
risk, also have disturbed esophageal motor function, leading to gastroesophageal reflux and development 
of Barrett’s esophagus.14 However, our study did not confirm a decreased risk of stroke. It is also important 
to note that patients with Barrett’s esophagus have been reported to have a high prevalence of 
hypertension.25 An inverse association between Barrett’s esophagus and stroke death based on a 
mechanism of decreased vascular tone/hypotension13 therefore seems unlikely.  
 
Study strengths include its population-based cohort design and a setting that provides equal and free 
access to healthcare, essentially eliminating referral bias. Complete follow-up of all patients prevented 
selection bias due to drop-out. In addition, we included only histologically verified diagnoses of Barrett’s 
esophagus and therefore limited biases stemming from exposure misclassification. Finally, we were able to 
include a population comparison cohort matched to the Barrett’s cohort on age, gender, and all conditions 
included in the Charlson Comorbidity Index. 
Our study also had several limitations. Among these, residual confounding from smoking, obesity, and 
alcohol consumption is a serious concern, as indicated by the analyses within subgroups of individuals with 
chronic obstructive pulmonary disease or alcoholism. Our findings also may have been influenced by 
unknown confounding and by misclassification. Although it is generally accepted that a diagnosis of 
Barrett’s esophagus should rely on the correlation between endoscopic and pathologic findings25, we used 
only  pathological findings. It is therefore possible that cases of cardia intestinal metaplasia or ultrashort (< 
1cm) Barrett’s esophagus were included, although international guidelines advise against taking routine 
 biopsies from the distal esophagus in the absence of endoscopic signs of Barrett’s esophagus.27 Although 
misclassification of our primary outcome (death) seems unlikely, it is well known that causes of death may 
be misclassified.15, 16 We also cannot rule out misclassification of the secondary endpoints, cardiovascular 
events. Finally, since guidelines recommend regular follow-up of patients with Barrett’s esophagus, our 
findings may be influenced by surveillance bias. 
In conclusion, we found that patients with Barrett’s esophagus were at 71% increased risk of overall 
mortality, and non-esophageal cancers and cardiovascular diseases were the main underlying causes of 
death. In addition, the rate of cardiovascular diseases was increased. Prophylactic measures against 
cardiovascular diseases and appropriate screening for non-esophageal cancers potentially could be even 
more important for improving prognosis in patients with Barrett’s esophagus than preventive measures 
against esophageal cancer, including surveillance endoscopy. 
  
 Table 1. Characteristics of patients with Barrett’s esophagus and a matched general population cohorta, 
Denmark 1997-2011. 
 Patients with Barrett’s esophagus Matched general population cohort a 
 Number (%) Number (%) 
Total 13,427 100.0 123,526 100.0 
Women 4,682 34.9 43,676 35.4 
Men 8,745 65.1 79,850 64.6 
Age at index date     
<49 2,827 21.1 27,779 22.5 
50-69 6,839 51.9 63,718 51.6 
70+ 3,761 28.0 32,029 25.9 
Year of index date     
1997-2001 3,323 24.7 31,075 25.2 
2002-2006 4,612 34.3 42,669 34.5 
2007-2011 5,492 40.9 49,782 40.3 
Comorbidities     
CCI score = 0 9,750 72.6 92,780 75.1 
CCI score = 1 1,957 14.6 16,842 13.6 
CCI score = 2+ 1,720 12.8 13,904 11.3 
Alcoholism 722 5.4 2,280 1.8 
Obesity 260 1.9 1,494 1.2 
Hypertension 1,214 9.0 6,982 5.7 
AFLI/AFLA  381 2.8 2,493 2.0 
Dysplasia/neoplasiab     
No dysplasia 10,843 80.8 N/A - 
Low-grade dysplasia 1,086 8.1 N/A - 
High-grade dysplasia 821 6.1 N/A - 
Esophageal cancer 677 5.0 256 0.2 
Abbreviations: AFLI/AFLA: Atrial fibrillation/flutter; CCI: Charlson’s Comorbidity Index 
a Matching criteria were age (5-year intervals), gender, year of index date, and comorbidity as defined by the 
Charlson’s Comorbidity Index. 
bAccording to the most severe degree of dysplasia/neoplasia during follow-up. 
 
 
  
 Table 2. Overall and cause-specific mortality among patients with Barrett’s esophagus and a matched general population cohort a, Denmark, 1997-
2011. 
Major causes of death  
(ICD-10 codes) 
N Person-
years 
Rate per 1000 
person-years 
 
Unadjusted HR 
 
Adjusted HR  
 
Adjusted HR <1 
year  
Adjusted HR 1-15 
years  
Overall mortality        
  Barrett´s esophagus 3,284 70,335 46.7 (45.1 - 48.3) 1.77 (1.70-1.84) 1.71 (1.64-1.77) 3.19 (2.95-3.44) 1.41 (1.34-1.48) 
  Population cohorta 19,521 718,912 27.2 (26.8 - 27.5) Ref. Ref. Ref. Ref. 
Neoplasms overall         
  Barrett´s esophagus 1,416 70,335 20.1 (19.1 - 21.2) 2.39 (2.25-2.55) 2.37 (2.23-2.52) 5.52 (4.97-6.13) 1.63 (1.51-1.77) 
  Population cohorta 6,381 718,912 8.9 (8.7 - 9.1) Ref. Ref. Ref. Ref. 
Neoplasm without 
esophageal cancer  
       
  Barrett´s esophagus 1,037 70,335 14.7 (13.9 - 15.7) 1.79 (1.67-1.92) 1.77 (1.65-1.90) 3.89 (3.46-4.39) 1.28 (1.18-1.40) 
  Population cohorta 6,175 718,912 8.6 (8.4 - 8.8) Ref. Ref. Ref. Ref. 
Esophageal cancer        
  Barrett´s esophagus 379 70,335 5.4 (4.9 - 5.9) 19.2 (16.0-23.1) 19.4 (16.1-23.4) 43.3 (30.4-61.7) 12.2 (9.67-15.4) 
  Population cohorta 206 718,912 0.3 (0.2 - 0.3) Ref. Ref. Ref. Ref. 
Circulatory system        
  Barrett´s esophagus 598 70,335 8.5 (7.8 - 9.2) 1.31 (1.20-1.44) 1.26 (1.15-1.38) 1.26 (0.99-1.59) 1.26 (1.14-1.39) 
  Population cohorta 4,753 718,912 6.6 (6.4 - 6.8) Ref. Ref. Ref. Ref. 
Respiratory system        
  Barrett´s esophagus 272 70,335 3.9 (3.4 - 4.3) 1.22 (1.07-1.39) 1.18 (1.04-1.36) 1.40 (1.03-1.91) 1.15 (0.99-1.33) 
  Population cohorta 2,177 718,912 3.0 (2.9 - 3.2) Ref. Ref. Ref. Ref. 
Digestive system        
  Barrett´s esophagus 307 70,335 4.4 (3.9 - 4.9) 2.60 (2.27-2.97) 2.40 (2.09-2.75) 4.15 (3.22-5.36) 1.97 (1.67-2.33) 
  Population cohorta 1,211 718,912 1.7 (1.6 - 1.8) Ref. Ref. Ref. Ref. 
All other causes        
  Barrett´s esophagus 668 70,335 9.5 (8.8 - 10.2) 1.49 (1.37-1.63) 1.41 (1.30-1.54) 1.96 (1.60-2.38) 1.32 (1.20-1.45) 
  Population cohorta 4,663 718,912 6.5 (6.3 - 6.7) Ref. Ref. Ref. Ref. 
Unknown causes of death        
  Barrett´s esophagus 23 70,335 0.3 (0.2 - 0.5) 0.70 (0.46-1.08) 0.71 (0.46-1.09) 1.31 (0.62-2.80) 0.57 (0.34-0.96) 
  Population cohorta 336 718,912 0.5 (0.4 - 0.5) Ref. Ref. Ref. Ref. 
Numbers in parentheses are 95% confidence intervals.  
a Matching criteria were age (5-year intervals), gender, year of index date, and comorbidity as defined by the Charlson Comorbidity Index. 
 Table 3. Mortality caused by malignancies among patients with Barrett’s esophagus and a matched general population cohort a, Denmark, 1997-2011. 
Major malignant causes of 
death  
(ICD-10 codes) 
N Person-
years 
Rate per 1000 
person-years 
Unadjusted HR Adjusted HR Adjusted HR <1 
year 
Adjusted HR 1-15 
years 
Oral and pharynx (C00-C14)         
  Barrett´s esophagus 22 70,335 0.3 (0.2 - 0.5) 1.59 (0.99-2.55) 1.33 (0.78-2.25) 0.56 (0.12-2.64) 1.54 (0.86-2.74) 
  Population cohorta 154 718,912 0.2 (0.2 - 0.2) Ref. Ref. Ref.  Ref. 
Digestive organs (C15-C26)        
  Barrett´s esophagus 790 70,335 11.2 (10.5 - 12.0) 4.84 (4.43-5.30) 4.80 (4.39-5.26) 12.4 (10.6-14.5) 2.92 (2.60-3.29) 
  Population cohorta 1,759 718,912 2.4 (2.3 - 2.6) Ref. Ref. Ref.  Ref. 
Esophagus (C15)        
  Barrett´s esophagus 379 70,335 5.4 (4.9 - 5.9) 19.2 (16.0-23.1) 19.2 (15.9-23.1) 40.6 (28.9-57.1) 12.2 (9.71-15.4) 
  Population cohorta 206 718,912 0.3 (0.2 - 0.3) Ref. Ref. Ref.  Ref. 
Stomach (C16)         
  Barrett´s esophagus 154 70,335 2.2 (1.9 - 2.5) 8.45 (6.71-10.6) 8.49 (6.74-10.7) 16.8 (11.5-24.6) 5.42 (4.00-7.33) 
  Population cohorta 188 718,912 0.3 (0.2 - 0.3) Ref. Ref. Ref.  Ref. 
Colorectum and anus (C18-C21)        
  Barrett´s esophagus 131 70,335 1.9 (1.6 - 2.2) 1.67 (1.37-2.02) 1.64 (1.35-1.99) 3.81 (2.71-5.35) 1.19 (0.93-1.52) 
  Population cohorta 844 718,912 1.2 (1.1 - 1.3) Ref. Ref. Ref.  Ref. 
Hepatobiliary system (C22-C24)        
  Barrett´s esophagus 42 70,335 0.6 (0.4 - 0.8) 2.33 (1.63-3.32) 2.29 (1.60-3.26) 7.48 (4.31-13.0) 1.06 (0.63-1.79) 
  Population cohorta 180 718,912 0.3 (0.2 - 0.3) Ref. Ref. Ref.  Ref. 
Pancreas (C25)        
  Barrett´s esophagus 71 70,335 1.0 (0.8 - 1.3) 2.36 (1.81-3.09) 2.33 (1.78-3.05) 6.66 (4.28-10.4) 1.37 (0.95-1.98) 
  Population cohorta 311 718,912 0.4 (0.4 - 0.5) Ref. Ref. Ref.  Ref. 
Lung and thorax (C30-C39)        
  Barrett´s esophagus 201 70,335 2.9 (2.5 - 3.3) 1.32 (1.13-1.53) 1.28 (1.10-1.49) 2.39 (1.81-3.15) 1.04 (0.86-1.25) 
  Population cohorta 1,587 718,912 2.2 (2.1 - 2.3) Ref. Ref. Ref.  Ref. 
Bones, connective tissue, and 
skin (C40-C49) 
       
  Barrett´s esophagus 28 70,335 0.4 (0.3 - 0.6) 1.45 (0.96-2.18) 1.37 (0.90-2.09) 2.51 (1.21-5.22) 1.08 (0.64-1.82) 
  Population cohorta 220 718,912 0.3 (0.3 - 0.3) Ref. Ref. Ref.  Ref. 
Breast (C50)        
  Barrett´s esophagus 50 70,335 0.7 (0.5 - 0.9) 1.94 (1.42-2.66) 1.95 (1.42-2.67) 2.69 (1.45-4.98) 1.77 (1.22-2.55) 
  Population cohorta 312 718,912 0.4 (0.4 - 0.5) Ref. Ref. Ref.  Ref. 
Genital organs (C51-C63)        
  Barrett´s esophagus 91 70,335 1.3 (1.0 - 1.6) 1.04 (0.83-1.30) 1.02 (0.82-1.28) 1.66 (1.07-2.59) 0.89 (0.69-1.16) 
  Population cohorta 922 718,912 1.3 (1.2 - 1.4) Ref. Ref. Ref.  Ref. 
 Kidney and urinary tract (C64-
C68) 
       
  Barrett´s esophagus 54 70,335 0.8 (0.6 - 1.0) 1.49 (1.11-2.01) 1.48 (1.10-1.99) 2.15 (1.22-3.82) 1.31 (0.92-1.85) 
  Population cohorta 417 718,912 0.6 (0.5 - 0.6) Ref. Ref. Ref.  Ref. 
Eyes and CNS (C69-C72)        
  Barrett´s esophagus 14 70,335 0.2 (0.1 - 0.3) 1.00 (0.57-1.75) 0.97 (0.55-1.71) 2.29 (0.75-7.04) 0.79 (0.41-1.53) 
  Population cohorta 141 718,912 0.2 (0.2 - 0.2) Ref. Ref. Ref.  Ref. 
Endocrine glands (C73-C75)        
  Barrett´s esophagus 1 70,335 0.0 (0.0 - 0.1) 0.60 (0.08-4.69) 0.58 (0.07-4.57) 4.27 (0.38-47.4) N/A 
  Population cohorta 17 718,912 0.0 (0.0 - 0.0) Ref. Ref. Ref.  Ref. 
Lymphoid, hematopoietic and 
others (C76-C97) 
       
  Barrett´s esophagus 145 70,335 2.1 (1.7 - 2.4) 2.06 (1.71-2.49) 2.05 (1.70-2.48) 5.57 (4.05-7.66) 1.33 (1.04-1.70) 
  Population cohorta 731 718,912 1.0 (0.9 - 1.1) Ref. Ref. Ref.  Ref. 
Numbers in parentheses are 95% confidence intervals.  
a Matching criteria were age (5-year intervals), gender, year of index, and comorbidity as defined by the Charlson Comorbidity Index. 
  
 Table 4. Overall and cause-specific mortality according to degree of dysplasia and neoplasia in patients with Barrett’s esophagus and in a matched 
general population cohort, Denmark, 1997-2011. 
Major causes of 
death  
(ICD-10 codes) 
Population  
Cohorta 
No dysplasia Low-grade dysplasia High-grade dysplasia Esophageal cancer 
Mortality  
ratesa 
Mortality 
ratesa 
Adjusted 
hazard ratiob 
Mortality 
ratesa 
Adjusted 
hazard ratiob 
Mortality 
ratesa 
Adjusted 
hazard ratiob 
Mortality 
ratesa 
Adjusted 
hazard ratiob 
Overall mortality 
27.2  
(26.8-27.5) 
38.3  
(36.8-39.9) 
1.40  
(1.34-1.46) 
51.2  
(45.0-57.5) 
1.43  
(1.26-1.61) 
69.2  
(59.7-78.7) 
1.79  
(1.56-2.06) 
345  
(315-376) 
10.0  
(9.14-11.0) 
Neoplasms overall  
8.9  
(8.7-9.1) 
13.0  
(12.1-13.9) 
1.47  
(1.37-1.59) 
18.7  
(15.0-22.5) 
1.74  
(1.42-2.13) 
34.3  
(27.6-41.0) 
2.94  
(2.41-3.58) 
306  
(277-335) 
25.9  
(23.4-28.5) 
Neoplasms without 
esophageal cancer  
8.6  
(8.4-8.8) 
12.3  
(11.4-13.1) 
1.44  
(1.34-1.56) 
17.0  
(13.4- 20.5) 
1.62  
(1.31-2.01) 
28.2  
(22.1-34.2) 
2.47  
(1.98-3.07) 
86.9  
(71.5-102) 
7.62  
(6.37-9.13) 
Esophageal cancer  
0.3  
(0.3-0.3) 
0.7  
(0.5-0.9) 
2.41  
(1.74-3.34) 
1.8  
(0.6-2.9) 
5.45  
(2.79-10.6) 
6.1  
(3.3- 8.9) 
18.8  
(11.6-30.5) 
220  
(195-244) 
511  
(425- 613) 
Circulatory system  
6.6  
(6.4-6.8) 
7.9  
(7.2-8.6) 
1.25  
(1.14-1.37) 
11.6  
(8.7-14.6) 
1.34  
(1.04-1.74) 
10.5  
(6.8-14.2) 
1.09  
(0.76-1.55) 
18.5  
(11.4-25.7) 
2.31  
(1.57-3.41) 
Respiratory system 
3.0  
(2.9-3.2) 
3.5  
(3.0-4.0) 
1.19  
(1.03-1.37) 
6.7  
(4.5-9.0) 
1.70  
(1.21-2.39) 
5.4  
(2.8- 8.1) 
1.25  
(0.76-2.05) 
6.4  
(2.2-10.6) 
1.73  
(0.90-3.34) 
Digestive system  
1.7  
(1.6-1.8) 
4.3  
(3.8-4.9) 
2.00  
(1.74-2.29) 
4.9  
(3.0-6.9) 
1.73  
(1.16-2.57) 
4.4  
(2.0- 6.8) 
1.71  
(0.99-2.96) 
3.6  
(0.4-6.7) 
1.61  
(0.67-3.88) 
All other causes 
6.5  
(6.3-6.7) 
9.3  
(8.6-10.1) 
1.40  
(1.28-1.52) 
8.7  
(6.1-11.2) 
0.96  
(0.71-1.29) 
14.2  
(9.9-18.6) 
1.50  
(1.10-2.03) 
10.0  
(4.8-15.2) 
1.31  
(0.78-2.21) 
Unknown causes of 
death 
0.5  
(0.4-0.5) 
0.3  
(0.2-0.4) 
0.65  
(0.40-1.05) 
0.6  
(0.0-1.3) 
1.05  
(0.34-3.28) 
0.3  
(0.0- 1.0) 
0.57  
(0.08-4.06) 
0.7  
(0.0-2.1) 
1.09  
(0.15-7.79) 
Numbers in parenthesis are 95% confidence intervals. 
a Rates per 1000 person-years. 
b Hazard ratios for the comparison of patients with Barrett’s esophagus to a general population cohort, adjusted for age (5-year intervals), gender, year of index date, 
Charlson Comorbidity Index score, atrial fibrillation/flutter, obesity, hypertension, and alcoholism. 
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Table 5. Incidence rates and hazard ratios (HRs) of cardiovascular diseases in patients with Barrett’s esophagus and a matched general population cohorta, Denmark, 
1997-2011. 
Outcome N Person-
years 
Rate per 1000 
person-years 
Unadjusted HR Adjusted HR Adjusted HR <1 year Adjusted HR 1-15 
years 
Myocardial infarction        
  Barrett´s esophagus 366 69,064 5.3 (4.8 - 5.9) 1.11 (1.00-1.24) 1.10 (0.99-1.24) 1.12 (0.85-1.47) 1.10 (0.98-1.25) 
  Population cohort 3,374 707,852 4.8 (4.6 - 4.9) Ref. Ref. Ref. Ref. 
Subarachnoid hemorrhage        
  Barrett´s esophagus 25 70,228 0.4 (0.2 - 0.5) 1.38 (0.90-2.12) 1.29 (0.83-2.00) 1.54 (0.64-3.71) 1.21 (0.72-2.01) 
  Population cohort 174 718,182 0.2 (0.2 - 0.3) Ref. Ref. Ref. Ref. 
Hemorrhagic stroke        
  Barrett´s esophagus 85 70,135 1.2 (1.0 - 1.5) 1.18 (0.94-1.49) 1.10 (0.87-1.39) 0.78 (0.41-1.49) 1.17 (0.91-1.50) 
  Population cohort 756 717,085 1.1 (1.0 - 1.1) Ref. Ref. Ref. Ref. 
Ischemic stroke        
  Barrett´s esophagus 333 69,318 4.8 (4.3 - 5.3) 1.21 (1.08-1.36) 1.18 (1.05-1.33) 1.23 (0.92-1.64) 1.17 (1.03-1.33) 
  Population cohort 2,781 710,376 3.9 (3.8 - 4.1) Ref. Ref. Ref. Ref. 
Venous thromboembolism        
  Barrett´s esophagus 295 69,523 4.2 (3.8 - 4.7) 1.70 (1.50-1.93) 1.65 (1.46-1.88) 3.11 (2.40-4.03) 1.40 (1.21-1.62) 
  Population cohort 1,813 713,902 2.5 (2.4 - 2.7) Ref. Ref. Ref. Ref. 
Congestive heart failure        
  Barrett´s esophagus 555 68,860 8.1 (7.4 - 8.7) 1.37 (1.25-1.50) 1.33 (1.21-1.46) 1.53 (1.23-1.90) 1.29 (1.16-1.43) 
  Population cohort 4,171 708,087 5.9 (5.7 - 6.1) Ref. Ref. Ref. Ref. 
Numbers in parentheses are 95% confidence intervals.  
a Matching criteria were age (5-year intervals), gender, year of index, and comorbidity as defined by the Charlson Comorbidity Index. 
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Figure legend 
Figure 1. Cumulative mortality curves for patients with Barrett’s esophagus and a matched general 
population cohort, Denmark, 1997-2011. 
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STROBE Statement—Checklist of items that should be included in reports of cohort studies  
 
Item 
No Recommendation 
 Title and abstract 1 (a) Indicate the study’s design with a commonly used term in the title or the 
abstract X 
(b) Provide in the abstract an informative and balanced summary of what was 
done and what was found X 
Introduction 
Background/rationale 2 Explain the scientific background and rationale for the investigation being reported 
X 
Objectives 3 State specific objectives, including any prespecified hypotheses X 
Methods 
Study design 4 Present key elements of study design early in the paper X 
Setting 5 Describe the setting, locations, and relevant dates, including periods of 
recruitment, exposure, follow-up, and data collection X 
Participants 6 (a) Give the eligibility criteria, and the sources and methods of selection of 
participants. Describe methods of follow-up X 
(b) For matched studies, give matching criteria and number of exposed and 
unexposed X 
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, and 
effect modifiers. Give diagnostic criteria, if applicable X 
Data sources/ 
measurement 
8*  For each variable of interest, give sources of data and details of methods of 
assessment (measurement). Describe comparability of assessment methods if 
there is more than one group X 
Bias 9 Describe any efforts to address potential sources of bias X 
Study size 10 Explain how the study size was arrived at X 
Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If applicable, 
describe which groupings were chosen and why X 
Statistical methods 12 (a) Describe all statistical methods, including those used to control for confounding 
X 
(b) Describe any methods used to examine subgroups and interactions X 
(c) Explain how missing data were addressed X 
(d) If applicable, explain how loss to follow-up was addressed X 
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(e) Describe any sensitivity analyses X 
Results 
Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers potentially 
eligible, examined for eligibility, confirmed eligible, included in the study, 
completing follow-up, and analysed X 
(b) Give reasons for non-participation at each stage X 
(c) Consider use of a flow diagram X 
Descriptive data 14* (a) Give characteristics of study participants (eg demographic, clinical, social) and 
information on exposures and potential confounders X 
(b) Indicate number of participants with missing data for each variable of interest X 
(c) Summarise follow-up time (eg, average and total amount) X 
Outcome data 15* Report numbers of outcome events or summary measures over time X 
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates 
and their precision (eg, 95% confidence interval). Make clear which confounders 
were adjusted for and why they were included X 
(b) Report category boundaries when continuous variables were categorized X 
(c) If relevant, consider translating estimates of relative risk into absolute risk for a 
meaningful time period X 
Other analyses 17 Report other analyses done—eg analyses of subgroups and interactions, and 
sensitivity analyses X 
Discussion 
Key results 18 Summarise key results with reference to study objectives X 
Limitations 19 Discuss limitations of the study, taking into account sources of potential bias or 
imprecision. Discuss both direction and magnitude of any potential bias X 
Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations, 
multiplicity of analyses, results from similar studies, and other relevant evidence X 
Generalisability 21 Discuss the generalisability (external validity) of the study results X 
Other information 
Funding 22 Give the source of funding and the role of the funders for the present study and, if 
applicable, for the original study on which the present article is based X 
 
*Give information separately for exposed and unexposed groups. 
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Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and 
published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely 
available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at 
http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is 
available at http://www.strobe-statement.org. 
 
 
